VivoSeq
Other

Mesenchymal Stem Cell

0

Pipeline Programs

18

Active Trials

2

Companies Involved

Mesenchymal Stem Cell is an early-stage landscape with 0 programs across 2 companies. The most active players are Taiwan Bio Therapeutics Inc., Hope Biosciences LLC.

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

68/100

Attrition Rate

11/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

61

clinical trials

Completed21 · 34%
Recruiting15 · 25%
Unknown status12 · 20%
Withdrawn4 · 7%
Terminated3 · 5%
Suspended3 · 5%
Other3 · 5%

Trial Activity

61 trials

Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)